Blood Cancer

GLOW: Assessing ibrutinib plus venetoclax in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses findings in the Phase III GLOW trial (NCT03462719), which assessed first-line ibrutinib plus venetoclax versus chlorambucil with obinutuzumab in patients with chronic lymphocytic leukemia (CLL). Patients receiving ibrutinib and venetoclax reported lower rates of relapse, and Dr Niemann suggests intermediate minimal residual disease (MRD) as an acceptable endpoint for certain patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.